Posttransplant lymphoproliferative disease after heart transplantation on Sandimmune therapy: treatment with interferon alfa-2b and intravenous immunoglobulin.
Ippoliti
G
G
Clinica Medica II, RCCS S. Matteo, Pavia, Italy.
Martinelli
L
L
Lorenzutti
F
F
Incardona
S
S
Negri
M
M
Balduzzi
P
P
Rovati
B
B
Ascari
E
E
Viganò
M
M
D015703:Antigens, CD / Q000097:blood; D015415:Biomarkers / Q000097:blood; D016572:Cyclosporine / Q000009:adverse effects*; D016179:Granulocyte Colony-Stimulating Factor / Q000097:blood; D016027:Heart Transplantation / Q000276:immunology* / Q000502:physiology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008232:Lymphoproliferative Disorders / Q000209:etiology* / Q000628:therapy; D017455:Receptors, IgE / Q000032:analysis; D015375:Receptors, Interleukin-2 / Q000032:analysis; D011994:Recombinant Proteins; D001613:beta 2-Microglobulin / Q000032:analysis
D015703:Antigens, CD; D015415:Biomarkers; D016756:Immunoglobulins, Intravenous; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D017455:Receptors, IgE; D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins; D001613:beta 2-Microglobulin; D016179:Granulocyte Colony-Stimulating Factor; D016572:Cyclosporine